Get the Stockscreener App
2.03
2.77%
-0.04
Therapeuticsmd Inc stock is traded at $2.03, with a volume of 56,590.
It is down -2.77% in the last 24 hours and down -2.30% over the past month.
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.
See More
Previous Close:
$2.07
Open:
$2.04
24h Volume:
56,590
Relative Volume:
1.56
Market Cap:
$23.50M
Revenue:
$3.35M
Net Income/Loss:
$86,000
P/E Ratio:
131.82
EPS:
0.0154
Net Cash Flow:
$2.67M
1W Performance:
-2.77%
1M Performance:
-2.30%
6M Performance:
-12.49%
1Y Performance:
+72.04%
1-Day Range:
$2.01
$2.045
1-Week Range:
$2.01
$2.1791
52-Week Range:
$0.99
$2.95
Therapeuticsmd Inc Stock (TXMD) Company Profile
Name
Therapeuticsmd Inc
Sector
Phone
561-961-1900
Address
951 YAMATO ROAD, SUITE 220, BOCA RATON, FL
Compare TXMD vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TXMD
Therapeuticsmd Inc
|
2.03 | 23.96M | 3.35M | 86,000 | 2.67M | 0.0154 |
TAK
Takeda Pharmaceutical Co Adr
|
17.36 | 56.30B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.45 | 42.85B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.585 | 42.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
72.72 | 30.49B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
506.95 | 21.43B | 3.17B | 1.29B | 1.01B | 27.09 |
Therapeuticsmd Inc Stock (TXMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-07-20 | Downgrade | Jefferies | Hold → Underperform |
| May-19-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-02-19 | Initiated | Guggenheim | Buy |
| Oct-17-19 | Initiated | H.C. Wainwright | Buy |
| Apr-30-19 | Resumed | Noble Capital Markets | Outperform |
| Jun-15-18 | Initiated | JP Morgan | Overweight |
| Sep-08-17 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-11-17 | Upgrade | Oppenheimer | Perform → Outperform |
| May-09-17 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-22-16 | Resumed | Jefferies | Buy |
| Nov-22-16 | Initiated | Oppenheimer | Outperform |
| Nov-07-16 | Resumed | Guggenheim | Buy |
| Apr-04-16 | Initiated | Goldman | Buy |
| Dec-08-15 | Reiterated | Jefferies | Buy |
| Dec-08-15 | Reiterated | Stifel | Buy |
| Sep-21-15 | Reiterated | Jefferies | Buy |
| Jun-09-15 | Initiated | Guggenheim | Buy |
| Jul-08-14 | Initiated | FBR Capital | Outperform |
| Apr-17-14 | Reiterated | Noble Financial | Buy |
| Jan-28-14 | Reiterated | Noble Financial | Buy |
View All
Therapeuticsmd Inc Stock (TXMD) Latest News
TherapeuticsMD, Inc. Revenue Breakdown – DUS:29TA - TradingView
TherapeuticsMD Q2 2026 License Revenue Drops 8.7% Year Over Year - clinicaltrialvanguard.com
TherapeuticsMD: Q2 Earnings Snapshot - AOL.com
TherapeuticsMD Q2 Net Income From Cont Ops US - Moomoo
TherapeuticsMD Q2 EPS drops 80% to $0.01 on sales slide - scanx.trade
Is TherapeuticsMD Inc (TXMD) Positioned for Growth After Q2 Earn - GuruFocus
TherapeuticsMD Q2 Results and Strategic Alternatives Review - TipRanks
TherapeuticsMD, Inc. Q2 2026: Revenue $869K, EPS $0.01— 10-Q Summary - TradingView
TherapeuticsMD Q2 license revenue falls; continues to evaluate strategic alternatives - TradingView
TherapeuticsMD Q2 2026 License Revenue Falls to $869000 - Quiver Quantitative
TherapeuticsMD Q2 2026 Earnings: License Revenue and Net Income Decline - TradingKey
TXMD: Q2 2026 saw lower net income and license revenue, with strategic alternatives under evaluation - TradingView
TherapeuticsMD (TXMD) posts Q2 2026 update and weighs strategic alternatives - Stock Titan
TherapeuticsMD to Recognize About $365K IMVEXXY Milestone in Q3 - Stock Titan
TherapeuticsMD, Inc. (29TA.SG) stock price, news, quote and history - Yahoo Finance Australia
TherapeuticsMD Inc. stock outperforms competitors on strong trading day - MarketWatch
Baselake group (TXMD) discloses 6.8% beneficial stake in TherapeuticsMD common stock - Stock Titan
CNSY Stock Price and Chart — NASDAQ:CNSY - TradingView
TherapeuticsMD, Inc. (29TA.SG) Stock Price, News, Quote & History - Yahoo! Finance Canada
TherapeuticsMD (TXMD) Holds Steady at $2.03 as Trading Range NarrowsVolume Rate Change - dars.gov.et
TXMD|TherapeuticsMD Inc|Price:2.090|Chg%:+0.060 - TradingKey
TherapeuticsMD Inc. (TXMD) Slips Further: Key Support Levels Under PressurePCR Spike - dars.gov.et
TherapeuticsMD Inc. stock outperforms competitors despite losses on the day - MarketWatch
TherapeuticsMD, Inc. Revenue Breakdown – SWB:29TA - TradingView
TherapeuticsMD Inc (TXMD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TherapeuticsMD Inc (TXMD) Cash Flow - TradingKey
TherapeuticsMD (TXMD) Holds Steady Near Key Support With Slight UptickCall Spread Alert - dars.gov.et
TherapeuticsMD Inc (TXMD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TherapeuticsMD Inc (TXMD) Valuation: PE, PB & Fair Value Analysis - TradingKey
TherapeuticsMD, Inc. Revenue Breakdown – MUN:29TA - TradingView
TherapeuticsMD Inc (TXMD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TherapeuticsMD Inc (TXMD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TXMD|TherapeuticsMD Inc|Price:2.060| - TradingKey
TXMD|TherapeuticsMD Inc|Price:2.070| - TradingKey
TherapeuticsMD (TXMD) Holds Steady at $2.06 as Consolidation ContinuesPut Support - dars.gov.et
TherapeuticsMD Inc (TXMD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TherapeuticsMD Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock underperforms Monday when compared to competitors - MarketWatch
TherapeuticsMD Company Profile & Introduction - Moomoo
TXMD Q3 2023 Earnings: Significant EPS Miss Amid Ongoing ChallengesEarnings Call Highlights - DonanımHaber
TherapeuticsMD (TXMD) News Flow - Moomoo
TherapeuticsMD (TXMD) Edges Higher, Consolidating Near $2.00Wave Truncation - dars.gov.et
TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors - MarketWatch
TXMD Q3 2023 Earnings: Significant EPS Miss Highlights Ongoing Revenue ChallengesReturn On Capital - dars.gov.et
TXMD Q3 2023 Earnings: Significant EPS Miss as Company Faces Operational ChallengesEarnings Risk Report - dars.gov.et
TherapeuticsMD (TXMD) Rallies 3.94% as Stock Approaches Key Resistance at $2.22Stop Run - dars.gov.et
TherapeuticsMD Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Price to earnings forward of TherapeuticsMD, Inc. – NASDAQ:TXMD - TradingView
Enterprise value to revenue forward of TherapeuticsMD, Inc. – NASDAQ:TXMD - TradingView
TherapeuticsMD Inc (TXMD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Therapeuticsmd Inc Stock (TXMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.76%
1.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):